Simeprevir, cetilistat set for first launches after Japan price listing
This article was originally published in Scrip
Executive Summary
Among the new therapeutics to be price listed in Japan on 19 November is Janssen Pharma's next-generation hepatitis C drug Sovriad (simeprevir; developed with Medivir), the step paving the way for what will be the first launch worldwide of the NS3/4A protease inhibitor.